SPARCL: Highly Effective Prevention of New Events with Atorvastatin after a Stroke

In patients with recent stroke or transient ischemic attack, the total number of vascular events prevented by atorvastatin was twice as high as the number of prevented index events.  

Doble antiagregación: menos es más en añosos.

In other words, the power of atorvastatin in secondary prevention is far superior to primary prevention. This gigantic reduction, both in index and recurrent events, gives us an idea of the clinical effectiveness of this drug in reducing vascular disease burden. 

The SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) compared atorvastatin against placebo in 4731 patients with recent stroke or transient ischemic attack with no history of CAD. 

This post hoc analysis measured the occurrence of all vascular events (primary and subsequent) and atorvastatin capacity to reduce them in each territory (cerebrovascular, coronary, peripheral).


Read also: ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries.


In the placebo group, an estimated first 41.2 and 62.7 total events every 100 patients at 6-year follow-up. For the atorvastatin group, event reduction included 177 fewer cerebrovascular events, 170 fewer coronary events and 43 fewer peripheral events (HR: 0.68, CI 95% 0.60 to 0.77).

This benefit translates into 20 fewer vascular events every 100 patients in the atorvastatin group over 6 years. 

Conclusion

In patients with recent stroke or transient ischemic attach atorvastatin significantly reduces the occurrence of new events in all vascular territories. The clinical efficacy of this drug to reduce disease burden is out of the question. 

Original Title: Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories in the SPARCL Trial. 

Reference: Michael Szarek et al. Journal of the American College of Cardiology (2020). Article in press. doi: https://doi.org/10.1016/j.jacc.2020.03.015


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...